Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $115,000.

  • Caribou Biosciences' Capital Expenditures fell 82.91% to $115,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 68.47%. This contributed to the annual value of $4.9 million for FY2024, which is 57.98% down from last year.
  • Per Caribou Biosciences' latest filing, its Capital Expenditures stood at $115,000 for Q3 2025, which was down 72.49% from $418,000 recorded in Q2 2025.
  • Caribou Biosciences' 5-year Capital Expenditures high stood at $4.8 million for Q3 2023, and its period low was $95,000 during Q1 2021.
  • Its 3-year average for Capital Expenditures is $1.6 million, with a median of $1.4 million in 2024.
  • In the last 5 years, Caribou Biosciences' Capital Expenditures spiked by 3,950.00% in 2021 and then crashed by 85.84% in 2024.
  • Caribou Biosciences' Capital Expenditures (Quarterly) stood at $685,000 in 2021, then surged by 156.50% to $1.8 million in 2022, then climbed by 29.60% to $2.3 million in 2023, then tumbled by 77.25% to $518,000 in 2024, then slumped by 82.91% to $115,000 in 2025.
  • Its Capital Expenditures was $115,000 in Q3 2025, compared to $418,000 in Q2 2025 and $1.0 million in Q1 2025.